Unrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia.
作者信息
Wu Liangliang, Liu Limin, Zhao Xin, Zhou Ming, Fu Andie, Zhang Yuping, Yang Wenrui, Chen Xiaowei, Mo Wenjian, Wang Caixia, Li Yumiao, Xu Shilin, Pan Shiyi, Zhou Ruiqing, Meng Fankai, Zhang Fengkui, Wu Depei, Wang Shunqing
机构信息
Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, Jiangsu, China.
出版信息
Blood Cancer J. 2024 Mar 6;14(1):37. doi: 10.1038/s41408-024-01021-x.
Abstract
摘要
相似文献
1
Unrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia.
Blood Cancer J. 2024 Mar 6;14(1):37. doi: 10.1038/s41408-024-01021-x.
2
Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
Transplant Cell Ther. 2022 Sep;28(9):586.e1-586.e7. doi: 10.1016/j.jtct.2022.05.027. Epub 2022 May 21.
3
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
J Hematol Oncol. 2022 Aug 12;15(1):105. doi: 10.1186/s13045-022-01324-1.
4
Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
Pediatr Hematol Oncol. 2021 Aug;38(5):417-419. doi: 10.1080/08880018.2021.1940579. Epub 2021 Jun 22.
5
Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
Pediatr Blood Cancer. 2018 Oct;65(10):e27290. doi: 10.1002/pbc.27290. Epub 2018 Jun 22.
6
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
N Engl J Med. 2022 Jan 6;386(1):11-23. doi: 10.1056/NEJMoa2109965.
7
First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.
Bone Marrow Transplant. 2024 Oct;59(10):1449-1457. doi: 10.1038/s41409-024-02377-1. Epub 2024 Aug 1.
8
Management of the refractory aplastic anemia patient: what are the options?
Hematology Am Soc Hematol Educ Program. 2013;2013:87-94. doi: 10.1182/asheducation-2013.1.87.
9
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
N Engl J Med. 2017 Apr 20;376(16):1540-1550. doi: 10.1056/NEJMoa1613878.
10
Hematopoietic cell transplantation for aplastic anemia.
Curr Opin Hematol. 2017 Nov;24(6):509-514. doi: 10.1097/MOH.0000000000000382.
引用本文的文献
1
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.
Blood Adv. 2025 Sep 9;9(17):4448-4457. doi: 10.1182/bloodadvances.2024015405.
本文引用的文献
1
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
J Hematol Oncol. 2022 Aug 12;15(1):105. doi: 10.1186/s13045-022-01324-1.
2
Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study.
Haematologica. 2022 Dec 1;107(12):2918-2927. doi: 10.3324/haematol.2022.280758.
3
Upfront unrelated donor hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: A retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation.
Am J Hematol. 2022 Jan 1;97(1):E1-E3. doi: 10.1002/ajh.26354. Epub 2021 Nov 28.
4
Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
Blood. 2022 Jan 6;139(1):34-43. doi: 10.1182/blood.2021012130.
5
Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia.
Leukemia. 2020 Dec;34(12):3359-3369. doi: 10.1038/s41375-020-0933-7. Epub 2020 Jun 26.
6
The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia.
Biol Blood Marrow Transplant. 2019 Sep;25(9):e277-e284. doi: 10.1016/j.bbmt.2019.05.012. Epub 2019 May 24.
7
Comparable Outcomes of First-Line Hematopoietic Stem Cell Transplantation from Unrelated and Matched Sibling Donors in Adult Patients with Aplastic Anemia: A Retrospective Single-Center Study.
Biol Blood Marrow Transplant. 2019 Aug;25(8):1567-1575. doi: 10.1016/j.bbmt.2019.03.020. Epub 2019 Mar 26.
8
Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment.
Blood Adv. 2018 Aug 14;2(15):2020-2028. doi: 10.1182/bloodadvances.2018021162.
9
Upfront Matched Unrelated Donor Transplantation in Aplastic Anemia.
Hematol Oncol Clin North Am. 2018 Aug;32(4):619-628. doi: 10.1016/j.hoc.2018.03.004. Epub 2018 May 28.
10
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
N Engl J Med. 2017 Apr 20;376(16):1540-1550. doi: 10.1056/NEJMoa1613878.
Zotero 插件